Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease

JR Rosh, T Lerer, J Markowitz, SR Goli… - Official journal of the …, 2009 - journals.lww.com
OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …
被引用次数：150 相关文章

Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric crohns disease

JR Rosh, T Lerer, J Markowitz… - American Journal …, 2009 - ohiostate.elsevierpure.com
OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease

JR Rosh, T Lerer, J Markowitz… - The American …, 2009 - pubmed.ncbi.nlm.nih.gov
Objectives Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease.

JR Rosh, T Lerer, J Markowitz, SR Goli… - American Journal of …, 2009 - search.ebscohost.com
OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease

JR Rosh, T Lerer, J Markowitz, SR Goli… - … American Journal of …, 2009 - search.proquest.com
OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Retrospective evaluation of the safety and effect of adalimumab therapy (RESEAT) in pediatric crohns disease

JR Rosh, T Lerer, J Markowitz, SR Goli… - American Journal of …, 2009 - pure.johnshopkins.edu
OBJECTIVES: Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in pediatric Crohn's disease.

JR Rosh, T Lerer, J Markowitz, SR Goli… - The American Journal …, 2009 - europepmc.org
Objectives Adalimumab, an anti-tumor necrosis factor immunoglobulin-1 antibody, is
increasingly being reported as a potential treatment option for children with moderate-to …

[引用][C] Retrospective Evaluation of the Safety and Effect of Adalimumab Therapy (RESEAT) in Pediatric Crohn's Disease

JR ROSH, T LERER, J MARKOWITZ… - The American …, 2009 - Nature Publishing Group